Praxair Stock To Go Ex-dividend Tomorrow (PX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- The ex-dividend date for Praxair (NYSE: PX) is tomorrow, September 5, 2012. Owners of shares as of market close today will be eligible for a dividend of 55 cents per share. At a price of $105.38 as of 9:30 a.m. ET, the dividend yield is 2.1%.

The average volume for Praxair has been one million shares per day over the past 30 days. Praxair has a market cap of $31.46 billion and is part of the basic materials sector and chemicals industry. Shares are down 1.3% year to date as of the close of trading on Friday.

Praxair, Inc. engages in the production, distribution, and sale atmospheric and process gases, as well as surface coatings in North America, Europe, South America, and Asia. The company has a P/E ratio of 18.9, equal to the average chemicals industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Praxair as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, good cash flow from operations, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. You can view the full Praxair Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing